News

Garmin Reveals First Running Watches With AMOLED Displays

The range-topping Forerunner 965 will cost $600 when released in late March, while the 265 model launches today for $450.

Published

1 year ago

March 3, 2023

Nour Nasir

Garmin

Garmin has unveiled two new GPS smartwatches with AMOLED displays: the Forerunner 965 and 265 series. The timepieces are labeled as dedicated running watches and provide “advanced training metrics” for athletes, heart-rate variability (HRV), sleep quality, training load and more.

The high-end Forerunner 965 model comes with a 1.4-inch AMOLED display, a decent 31 hours of GPS-mode battery life and up to 23 days of use as a smartwatch. The flagship model of the series features additional performance stats over the cheaper 265, including training load ratio, stamina info and detailed climbing metrics (including gradient, distance and elevation).

The Forerunner 265 Series comes in two sizes (42mm and 46mm) and holds out for 24 hours in GPS mode or 15 days in smartwatch mode.

All of the watches in the series use Pulse Ox sensors, and offer “Body Battery” monitoring, sleep and stress stats, menstrual cycle and pregnancy tracking. As well as featuring adaptive training options and suggested workouts, the Garmin 965 and 265 both monitor v02 max and other important performance metrics.

Also Read: Best Music Streaming Services In The Middle East

The Forerunner 965 will cost $600 when it hits stores in “late March”, while the cheaper Forerunner 265 is available now for $450.

News

Orchid Plans To Find Out What’s Wrong With You Before You’re Born

According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.

Published

1 hour ago

May 7, 2024

Nour Nasir

Orchid

Each day, around 400,000 babies are welcomed into the world. However, among those, a growing number will experience some kind of birth defect or inherited disease.

Noor Siddiqui, CEO of Orchid, hopes to “mitigate” unpleasant genetic surprises using genome sequencing technology to reveal a wealth of genetic information on which newborns will grow into healthy adults.

Until 2019, IVF specialists had access to under 1% of the human genome. The tests, called PGT-A and PGT-M, scanned a mere 1,000 data points in a genome comprising around 3 billion bases, offering a very limited dataset compared to the technology used by Orchid.

“Our chromosomes are like chapters in a book that make up the table of contents.” Explained Siddiqui. “[PGT-A and PGT-M tests] only examine the table of contents, whereas what Orchid is doing is like a spellcheck on the entire book.” Orchid’s genome sampling technology assesses “100 times the data, covering many more conditions.” In essence, an Orchid report covers three categories of common genetic issues: monogenic disorders, polygenic conditions, and de-novo mutations.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Orchid’s technology raises many questions. Aside from the obvious ethical concerns, data privacy is the most obvious potential issue with the tests. Noor Siddiqui is keen to alleviate any concerns: “No data at Orchid is ever sold to any third parties. Parents are in complete control of their data. If they want to delete the data, we’re happy to delete it off of our servers. If they want to export the data, they can export the data. And if they want us to re-analyze the data, we can re-analyze the data”.

Compared to a lifetime of medical bills, gene therapy, and suffering, Orchid’s genome screening report has the potential to change the future lives of thousands of newborns worldwide.